



SolAeroMed Inc.  
Unit 2, Research Transition Facility  
3535 Research Road N.W.  
Calgary, AB, T2L 2K8

SolAeroMed Shareholder Newsletter #13 September 24, 2015

Hello SAMi shareholders

Thank you to those who joined our Board meeting on June 30<sup>th</sup>. Minutes are posted on [www.solaeromed.com](http://www.solaeromed.com). This newsletter is intended to update shareholders on recent progress. Despite overcoming a few glitches, all continues to go well here at SolAeroMed !

An early spring in Alberta, resulted in an early pollen season which delayed progress of patient recruitment in our S-1226 Phase II Proof of Concept trial. Even so, the clinical site, under the direction of Prof Richard Leigh, has now completed n=9 of the anticipated n=12 test subjects. We anticipate full completion of the S-1226 trial by December 2015. In anticipation of successful results we have been actively seeking development and/or licensing partners for S-1226 on multiple fronts, including:

- Promoting S-1226 through our professional networks and [University press](#)
- S-1226 [presentation](#) at American Thoracic Society Denver, May 2015
- Industry partnership event BioTrinity, London, UK May 2015
- Industry partnership event [BIO2015](#) Philadelphia, USA, June 2015
- Regional investment forums through [Tek Edmonton](#) & [VA Angels](#)
- S-1226 Drug and Device research at the [European Respiratory Society](#) (Amsterdam) Sept 2015

It is challenging for any small biotechnology company to attract attention, and we are pleased to share that SolAeroMed S-1226 is already on the radar of potential License and Development partners and we are currently actively sharing information and exploring partnerships under CDA with a half dozen potential partners.

In addition to advancing clinical development of S-1226, we are progressing our understanding S-1229 to treat dysfunctional lung surfactant. We have also expanded our understanding of drug/device technology for the treatment of Sleep Apnea. Over the summer we hired 3 MBT graduates to support R&D around our drug and device technologies. Of these, Asma Amir Ali and Ruchika Sharma have now been accepted into Medical School with our congratulations, while we have retained Gurkeet Lalli to continue to support SolAeroMed R&D. Harm Deckers has been appointed to coordinate our expanding patent portfolio. We continue pursue non-dilutive grant funding to support R&D, as well as further investment in SolAeroMed to provide more financial runway for our licensing negotiations.

The remaining months of 2015 will be busy and exciting times. We will continue to expand our technology R&D, pipeline and patents within our unique biotechnology space of 'BioPhysical Respiratory Drugs and Devices'. We have confidence our lead S-1226 asthma drug will prove safe and effective in treating asthma in our ongoing Phase II Proof of Concept Trial, and we have every reason to anticipate we will find a suitable development partner, and negotiate favourable Terms to the benefit both of Development Partner and SolAeroMed shareholders.

We will continue to update shareholders through periodic newsletters and [www.solaeromed.com](http://www.solaeromed.com). Our next newsletter is planned towards the end of the year, when we hope to share news of successful safety and efficacy results from our S-1226 Phase II clinical trial and business development. Shareholders are invited to contact management directly with specific questions or concerns.

John Dennis, PhD CEO, SolAeroMed  
[jdennis@solaeromed.com](mailto:jdennis@solaeromed.com) +1 403 689 5989